Company profile
NovaGo Therapeutics
Clinical-stage biotechnology company developing anti-Nogo-A biologics for diseases of the central nervous system. The CHF 24 million (USD 30 million) Series B, complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life, will advance its lead program into a proof-of-concept study in patients with acute spinal cord injury.
- Location
- Schlieren, Switzerland
- Website
- novagotherapeutics.com
Latest known funding
Series B round
- Capital
- $30M
- Announced
- Sep 2, 2026